Brian Bettencourt,Stuart Milstein,Ivanka Toudjarska,Earl McDonald,Michael Schlabach, JR.,Frank P. Stegmeier,Markus Warmuth,Kalyani Gampa,Dieter Huesken,Mark Stump,Jan Weiler,Zainab Jagani
申请号：
US15258042
公开号：
US20180153919A1
申请日:
2016.09.07
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The present disclosure relates to RNAi agents useful in methods of treating KRAS-related diseases such as a proliferative disease, including without limitation a solid or liquid cancer, adenocarcinoma, colorectal cancer, advanced and/or metastatic colorectal cancer, colon cancer, lung, non-small cell lung cancer and lung adenocarcinoma, acute myelogenous lung, bladder, brain, breast, cervical, endometrial, gastric, head and neck, kidney, leukemia, myelodysplastic syndrome, myeloid leukemia, liver, melanoma, ovarian, pancreatic, prostate, testicular, thyroid cancers, and cardio-facio-cutaneous (CFC) syndrome and Noonan syndrome, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to KRAS.
